Edition:
United States

ESSA Pharma Inc (EPIX.OQ)

EPIX.OQ on NASDAQ Stock Exchange Capital Market

3.55USD
20 Jul 2018
Change (% chg)

$0.00 (+0.07%)
Prev Close
$3.55
Open
$3.70
Day's High
$3.70
Day's Low
$3.36
Volume
8,081
Avg. Vol
3,925
52-wk High
$12.40
52-wk Low
$2.78

Chart for

About

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen... (more)

Overall

Beta: 0.29
Market Cap(Mil.): $28.33
Shares Outstanding(Mil.): 5.78
Dividend: --
Yield (%): --

Financials

  EPIX.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -0.51 -- --
ROI: -34.22 -3.65 13.18
ROE: -129.11 -5.62 15.09

BRIEF-Essa Pharma Qtrly Loss Per Share Of $0.83

* ESSA PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FINANCIAL RESULTS FOR FISCAL SECOND QUARTER ENDED MARCH 31, 2018

May 14 2018

BRIEF-ESSA Pharma Inc. Regains Compliance With Nasdaq Listing Requirements

* ESSA PHARMA INC. REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS Source text for Eikon: Further company coverage:

May 10 2018

BRIEF-Essa Pharma Files For Resale Of 113.9 Mln Common Shares By Selling Shareholders

* ESSA PHARMA INC FILES FOR RESALE OF CO'S 113.9 MILLION COMMON SHARES BY SELLING SHAREHOLDERS - SEC FILING Source: (http://bit.ly/2Ft0Xh1) Further company coverage:

Mar 06 2018

BRIEF-Essa Pharma Qtrly Loss Per Share $0.07

* ESSA PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FINANCIAL RESULTS FOR FISCAL FIRST QUARTER ENDED DECEMBER 31, 2017

Feb 13 2018

BRIEF-Essa Pharma Files For Offering Of About 113.9 Million Common Shares That May Be Offered For Resale By Selling Shareholders

* ESSA PHARMA INC FILES FOR OFFERING OF ABOUT 113.9 MILLION COMMON SHARES THAT MAY BE OFFERED FOR RESALE BY SELLING SHAREHOLDERS - SEC FILING Source text: (http://bit.ly/2Dsiula) Further company coverage:

Jan 22 2018

Earnings vs. Estimates